Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations

Patrick O. Richard; Philippe D. Violette; Bimal Bhindi; Rodney H. Breau; Wassim Kassouf; Luke T. Lavallée; Michael Jewett; John R. Kachura; Anil Kapoor; Maxine Noel-Lamy; Michael Ordon; Stephen E. Pautler; Frédéric Pouliot; Alan I. So; Ricardo A. Rendon; Simon Tanguay; Christine Collins; Maryam Kandi; Bobby Shayegan; Andrew Weller; Antonio Finelli

doi:10.5489/cuaj.7760

Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations

Patrick O. Richard, Philippe D. Violette, Bimal Bhindi, Rodney H. Breau, Wassim Kassouf, Luke T. Lavallée, Michael Jewett, John R. Kachura, Anil Kapoor, Maxine Noel-Lamy, Michael Ordon, Stephen E. Pautler, Frédéric Pouliot, Alan I. So, Ricardo A. Rendon, Simon Tanguay, Christine Collins, Maryam Kandi, Bobby Shayegan, Andrew WellerAntonio Finelli

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	24-25
Number of pages	2
Journal	Journal of the Canadian Urological Association
Volume	16
Issue number	2
DOIs	https://doi.org/10.5489/cuaj.7760
Publication status	Published - Feb 2022
Externally published	Yes

ASJC Scopus Subject Areas

Urology

Access to Document

10.5489/cuaj.7760

Cite this

Richard, P. O., Violette, P. D., Bhindi, B., Breau, R. H., Kassouf, W., Lavallée, L. T., Jewett, M., Kachura, J. R., Kapoor, A., Noel-Lamy, M., Ordon, M., Pautler, S. E., Pouliot, F., So, A. I., Rendon, R. A., Tanguay, S., Collins, C., Kandi, M., Shayegan, B., ... Finelli, A. (2022). Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations. Journal of the Canadian Urological Association, 16(2), 24-25. https://doi.org/10.5489/cuaj.7760

Richard, PO, Violette, PD, Bhindi, B, Breau, RH, Kassouf, W, Lavallée, LT, Jewett, M, Kachura, JR, Kapoor, A, Noel-Lamy, M, Ordon, M, Pautler, SE, Pouliot, F, So, AI, Rendon, RA, Tanguay, S, Collins, C, Kandi, M, Shayegan, B, Weller, A & Finelli, A 2022, 'Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations', Journal of the Canadian Urological Association, vol. 16, no. 2, pp. 24-25. https://doi.org/10.5489/cuaj.7760

@article{dc1ac5ed8a884cf9889b55107333bf8e,

title = "Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations",

author = "Richard, {Patrick O.} and Violette, {Philippe D.} and Bimal Bhindi and Breau, {Rodney H.} and Wassim Kassouf and Lavall{\'e}e, {Luke T.} and Michael Jewett and Kachura, {John R.} and Anil Kapoor and Maxine Noel-Lamy and Michael Ordon and Pautler, {Stephen E.} and Fr{\'e}d{\'e}ric Pouliot and So, {Alan I.} and Rendon, {Ricardo A.} and Simon Tanguay and Christine Collins and Maryam Kandi and Bobby Shayegan and Andrew Weller and Antonio Finelli",

note = "Funding Information: Competing interests: Dr. Richard has been an advisory board member for Bayer, Janssen, and Sanofi; and a speakers{\textquoteright} bureau member for Abbvie, Amgen, Astellas, Ferring, and Janssen. Dr. Bhindi has been an advisory board member for Bayer and Janssen; and has received speaker honoraria from Merck. Dr. Breau has been an advisory board member for Ferring (bladder cancer). Dr. Kassouf has been an advisory board member for EMD Serono and Pfizer; has received grants and/or honoraria from Abbvie, Astellas, BMS, Ferring, Janssen, Merck, Roche, and Sesen Bio; and has participated in clinical trials supported by Astra Zeneca, BMS, Janssen, Pfizer, Roche, Sesen Bio, and Theralase. Dr. Lavall{\'e}e has participated in advisory boards for Abbvie, Bayer, Ferring, Sanofi, and Tersera; and has received an unrestricted research grant from Sanofi. Dr. Jewett has been an advisory board member for and received payment from Sesen Bio and Theralase Technologies Ltd. Dr. Kachura participated in the multicenter OPTIMA trial for liver cancer ablation supported by Celsion Inc. Dr. Pouliot has been an advisory board member for Astellas, Bayer, Esai, Janssen, Merck, Sanofi, and Tersera; holds investments in Allogene Therapeutics; and has participated in clinical trials supported by Lantheus, Merck, and Progenics. Dr. So has been an advisory board member for Abbvie, Amgen, Bayer, Ferring, Janssen, Merck, and Tersera. Dr. Rendon has been an advisory board and speakers{\textquoteright} bureau member for and has received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. Dr. Tanguay has participated in advisory boards for BMS, Janssen, Knight Therapeutics, Merck, and Roche; and has participated in clinical trials supported by AstraZeneca and Roche. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Nayak has been an advisory board member for Merck and Sanofi; and a speakers{\textquoteright} bureau member for Astellas, Sanofi, and Tersera. The remaining authors do not report any competing personal or financial interests related to this work.",

year = "2022",

month = feb,

doi = "10.5489/cuaj.7760",

language = "English",

volume = "16",

pages = "24--25",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "2",

}

TY - JOUR

T1 - Canadian Urological Association guideline

T2 - Management of small renal masses - Summary of recommendations

AU - Richard, Patrick O.

AU - Violette, Philippe D.

AU - Bhindi, Bimal

AU - Breau, Rodney H.

AU - Kassouf, Wassim

AU - Lavallée, Luke T.

AU - Jewett, Michael

AU - Kachura, John R.

AU - Kapoor, Anil

AU - Noel-Lamy, Maxine

AU - Ordon, Michael

AU - Pautler, Stephen E.

AU - Pouliot, Frédéric

AU - So, Alan I.

AU - Rendon, Ricardo A.

AU - Tanguay, Simon

AU - Collins, Christine

AU - Kandi, Maryam

AU - Shayegan, Bobby

AU - Weller, Andrew

AU - Finelli, Antonio

N1 - Funding Information: Competing interests: Dr. Richard has been an advisory board member for Bayer, Janssen, and Sanofi; and a speakers’ bureau member for Abbvie, Amgen, Astellas, Ferring, and Janssen. Dr. Bhindi has been an advisory board member for Bayer and Janssen; and has received speaker honoraria from Merck. Dr. Breau has been an advisory board member for Ferring (bladder cancer). Dr. Kassouf has been an advisory board member for EMD Serono and Pfizer; has received grants and/or honoraria from Abbvie, Astellas, BMS, Ferring, Janssen, Merck, Roche, and Sesen Bio; and has participated in clinical trials supported by Astra Zeneca, BMS, Janssen, Pfizer, Roche, Sesen Bio, and Theralase. Dr. Lavallée has participated in advisory boards for Abbvie, Bayer, Ferring, Sanofi, and Tersera; and has received an unrestricted research grant from Sanofi. Dr. Jewett has been an advisory board member for and received payment from Sesen Bio and Theralase Technologies Ltd. Dr. Kachura participated in the multicenter OPTIMA trial for liver cancer ablation supported by Celsion Inc. Dr. Pouliot has been an advisory board member for Astellas, Bayer, Esai, Janssen, Merck, Sanofi, and Tersera; holds investments in Allogene Therapeutics; and has participated in clinical trials supported by Lantheus, Merck, and Progenics. Dr. So has been an advisory board member for Abbvie, Amgen, Bayer, Ferring, Janssen, Merck, and Tersera. Dr. Rendon has been an advisory board and speakers’ bureau member for and has received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. Dr. Tanguay has participated in advisory boards for BMS, Janssen, Knight Therapeutics, Merck, and Roche; and has participated in clinical trials supported by AstraZeneca and Roche. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Nayak has been an advisory board member for Merck and Sanofi; and a speakers’ bureau member for Astellas, Sanofi, and Tersera. The remaining authors do not report any competing personal or financial interests related to this work.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85124847561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124847561&partnerID=8YFLogxK

U2 - 10.5489/cuaj.7760

DO - 10.5489/cuaj.7760

M3 - Article

AN - SCOPUS:85124847561

SN - 1911-6470

VL - 16

SP - 24

EP - 25

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 2

ER -

Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this